Lecturas recomendadas comentadas

2022

octubre

  • Incidence and aetiology of infant Gram-negative bacteraemia and meningitis: systematic review and meta-analysis
  • Revisado por: Carlos Rodrigo Gonzalo de Liria
  • Grupo de trabajo: Infecciones bacterianas
  • Referencia: Hallmaier-Wacker LK, Andrews A, Nsonwu O, et al. Arch Dis Child Epub ahead of print. doi:10.1136/ archdischild-2022-324047
  • Descargar:   PDF
  • Multicenter Prospective Study of Biomarkers for Diagnosis of Invasive Candidiasis in Children and Adolescents
  • Revisado por: Natalia Mendoza Palomar
  • Grupo de trabajo: Infección Fúngica Invasiva
  • Referencia: Fisher BT, Boge CLK, Xiao R, et al. Multicenter Prospective Study of Biomarkers for Diagnosis of Invasive Candidiasis in Children and Adolescents. Clin Infect Dis. 2022 Jan 20:ciab928. doi: 10.1093/cid/ciab928.
  • Descargar:   PDF

septiembre

  • Change Over Time in Seasonality and Severity of Children Hospitalized With Respiratory Syncytial Virus Infection in Japan
  • Revisado por: Cristian Launes
  • Grupo de trabajo: Infecciones Respiratorias
  • Referencia: Ozeki S, Oshiro M, Fukumi D, et al. Change Over Time in Seasonality and Severity of Children Hospitalized With Respiratory Syncytial Virus Infection in Japan. Pediatr Infect Dis J. 2022. doi: 10.1097/INF.0000000000003568.
  • Descargar:   PDF
  • Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria
  • Revisado por: Antoni Soriano Arandes
  • Grupo de trabajo: Patología Importada
  • Referencia: Wu RL, Idris AH, Berkowitz NM, Happe M, Gaudinski MR, Buettner C, et al. Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria. N Engl J Med. 2022 Aug 4; 387(5):397-407. doi: 10.1056/NEJMoa2203067
  • Descargar:   PDF

julio

  • Extended Infusion of Beta-Lactams Is Associated With Improved Outcomes in Pediatric Patients.
  • Revisado por: Ana Isabel Menasalvas Ruiz
  • Grupo de trabajo: Infecciones relacionadas con la asistencia sanitaria
  • Referencia: Zembles TN, Schortemeyer R, Kuhn EM, et al. Extended Infusion of Beta-Lactams Is Associated With Improved Outcomes in Pediatric Patients. J Pediatr Pharmacol Ther. 2021; 26:187-193. doi: 10.5863/1551-6776-26.2.187.
  • Descargar:   PDF

junio

  • Evidence of Artemisinin-Resistant Malaria in Africa
  • Revisado por: David Torres y Luis M. Prieto
  • Grupo de trabajo: Patología Importada
  • Referencia: Balikagala B, Fukuda N, Ikeda M, et al. Evidence of Artemisinin-Resistant Malaria in Africa. N Engl J Med. 2021;385:1163-71
  • Descargar:   PDF

mayo

  • Urinary Proadrenomedullin and Disease Severity in Children With Suspected Community-acquired Pneumonia
  • Revisado por: José Antonio Couceiro Gianzo
  • Grupo de trabajo: Infecciones Respiratorias
  • Referencia: Florin TA, Ambroggio L, Shah SS, Ruddy RM, Nylen ES, Balmert L. Urinary Proadrenome-dullin and Disease Severity in Children With Suspected Community-acquired Pneumonia. Pediatr Infect Dis J 2021 Dec1;40(12):1070–1075.
  • Descargar:   PDF

abril

  • Duration of Antibiotic Therapy in Neonatal Gram-negative Bacterial Sepsis-10 Days Versus 14 Days: A Randomized Controlled Trial
  • Revisado por: Laura Martín Pedraz
  • Grupo de trabajo: Infecciones relacionadas con la asistencia sanitaria
  • Referencia: Fursule A, Thakur A, Garg P, Kler N. Duration of Antibiotic Therapy in Neonatal Gram-negative Bacterial Sepsis-10 Days Versus 14 Days: A Randomized Controlled Trial. Pediatr Infect Dis J 2022. 41;2:156-160
  • Descargar:   PDF
  • Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018
  • Revisado por: Enrique Otheo
  • Grupo de trabajo: Infecciones Respiratorias
  • Referencia: Hansen CL, Chaves SS, Demont C, Viboud C. Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018. JAMA Netw Open. 2022 Feb; 5(2):e220527. doi: 10.1001/jamanetworkopen.2022.0527.
  • Descargar:   PDF

marzo

  • Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
  • Revisado por: María José Muñoz Vilches
  • Grupo de trabajo: Patología Importada
  • Referencia: Jaime AltchehI, Luis CastroI, Juan C. Dib, et al. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO). PLOS Neglected Tropical Diseases https://doi.org/10.1371/journal.pntd.0008912 January 7, 2021
  • Descargar:   PDF